NHS access guide
How to Get Mounjaro on the NHS for Weight Loss: The Full Guide
Mounjaro is available on the NHS for weight management, but only to a narrow group so far, and who qualifies depends on which phase of the rollout is open and whether your GP practice is taking part. This guide sets out the current criteria in plain terms, how the pathway works in 2026, what happens if you are already paying privately, and what your options are if you do not qualify.
Key facts
- NICE recommended tirzepatide for NHS use in December 2024 (TA1026) for adults with a BMI of 35 or more and at least one weight-related condition, with lower thresholds for some ethnic backgrounds.
- NHS England is introducing it in phases over up to 12 years. In primary care, only the first two phases are open: since 23 June 2025, BMI 40 or more with at least four of five named conditions; since 23 June 2026, BMI 35 to 39.9 with at least four of the five.
- The five conditions are type 2 diabetes, high blood pressure, high cholesterol or triglycerides, established cardiovascular disease, and obstructive sleep apnoea. All must be formally diagnosed and on your record.
- From 1 April 2026 GP practices can prescribe it under the GP contract, but taking part is voluntary and funded locally, so availability differs by area and practice.
- NHS treatment comes with mandatory lifestyle support for at least nine months and is dispensed on a normal NHS prescription, so the usual prescription charge or exemption applies.
- Most people who meet the licence criteria (BMI 30, or 27 with a condition) do not currently qualify on the NHS and are treated privately.
Three sets of rules, and why people get confused
Much of the frustration around NHS Mounjaro comes from mixing up three different things:
- The licence sets who a prescriber may treat at all: BMI 30 or more, or 27 or more with a weight-related condition. Private pharmacies work to this.
- NICE guidance (TA1026) sets who the NHS should fund: BMI 35 or more with at least one condition.
- NHS England’s rollout plan sets who can actually be treated in each phase, which is narrower again because of capacity and cost.
So it is possible to read that NICE recommends Mounjaro, meet the NICE threshold, and still be told by your GP that you do not qualify yet. That is usually correct rather than a mistake, because primary care access is being widened one phase at a time.
Who qualifies in primary care right now
| Phase | Open from | BMI (adjusted for listed ethnic backgrounds) | Conditions required |
|---|---|---|---|
| Cohort 1 | 23 June 2025 | 40 or more (37.5 or more) | At least 4 of the 5 |
| Cohort 2 | 23 June 2026 | 35 to 39.9 (32.5 to 37.4) | At least 4 of the 5 |
| Cohort 3 | 1 April 2027 (planned) | 40 or more (37.5 or more) | At least 3 of the 5 |
The five qualifying conditions are type 2 diabetes, hypertension, dyslipidaemia, established cardiovascular disease and obstructive sleep apnoea. The lower BMI figures apply to people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, following NICE guideline NG246. NHS England estimates the first three years will cover around 220,000 people in England.
Specialist weight-management services (sometimes called tier 3) can work to the wider NICE criteria where they have capacity, so a referral there may open access sooner than waiting for a primary-care phase. Waiting times vary widely by region.
How the pathway works
- Check your record. The conditions must be coded diagnoses, not self-reported. If you believe you have one that is not on your record, ask for it to be assessed first.
- Ask your GP practice whether it is taking part. From April 2026 tirzepatide prescribing sits in the GP contract as an optional indicator. Practices that have not opted in can refer you to one that has, or to the local weight-management service, but they cannot prescribe it themselves.
- Assessment. A clinician confirms BMI, conditions, contraindications and other medicines, and discusses expectations and side effects.
- Wraparound support. NHS England requires access to dietary advice and behaviour-change support for at least nine months. This is a condition of treatment, not an optional extra.
- Prescription and reviews. Treatment starts at 2.5 mg and steps up as tolerated. Reviews check weight, side effects and, in diabetes, blood sugar. NICE expects treatment to be reviewed rather than open-ended.
If you already pay privately
Being on Mounjaro privately does not disqualify you from NHS treatment, but it does not shortcut it either. You must meet the phase criteria that apply at the time, and local services will assess you afresh; some ask for your private treatment history and current dose. If you do move across, ask your private pharmacy for a summary and keep your last order screenshots and pen-box photos, as you would when switching pharmacy. Do not run an NHS and a private supply at the same time.
What it costs on the NHS
Mounjaro on the NHS is dispensed as a normal prescription item. In England that means the standard prescription charge per item unless you are exempt, for example because of age, income-related benefits, a medical exemption certificate (which includes diabetes treated with medicine) or a prepayment certificate. Prescriptions are free in Scotland, Wales and Northern Ireland, though each nation has its own approval and rollout arrangements for tirzepatide, and access there does not follow the English phases exactly.
If you do not qualify yet
For most people with a BMI between 30 and 35, or 35 to 40 with fewer than four conditions, NHS access is years away. The realistic options are:
- Private prescribing through a GPhC-registered pharmacy that works to the licence criteria. Prices differ a lot between providers and change often; the Monj price comparison ranks every verified pharmacy by total cost including delivery and is updated daily.
- NHS lifestyle services, including the NHS Digital Weight Management Programme and local tier 2 programmes, which your GP can refer you to regardless of the medicine rollout.
- Other NHS-funded medicines where you meet their criteria, such as semaglutide (Wegovy) through specialist services, or orlistat.
Whatever route you take, the eligibility rules a private prescriber must follow are set out in our BMI requirements guide.
Common questions
Can my GP prescribe Mounjaro for weight loss?
Only if the practice has opted into the NHS scheme and you meet the criteria of an open phase. Otherwise the GP can refer you to a participating practice or to a specialist weight-management service.
I have a BMI of 32 and type 2 diabetes. Do I qualify?
Not in primary care under the current phases, which start at BMI 35 with four conditions. Tirzepatide is also licensed for type 2 diabetes, and your diabetes team may consider it under that separate NICE guidance (TA924), which has its own criteria.
Is Mounjaro free on the NHS?
It carries the normal prescription charge in England unless you are exempt, and is free in Scotland, Wales and Northern Ireland. There is no additional charge for the medicine itself.
When will the NHS offer it at a BMI of 30?
No date has been set. NHS England’s plan runs over up to 12 years and the published phases so far only reach BMI 35 with multiple conditions. On that trajectory, primary-care access at BMI 30 with one condition is many years away.
Sources
- National Institute for Health and Care Excellence. Tirzepatide for managing overweight and obesity (TA1026), December 2024.
- NHS England. Interim commissioning guidance: implementing NICE TA1026 tirzepatide for managing overweight and obesity, March 2025.
- NHS England. GP contract 2026/27, including Quality and Outcomes Framework changes.
- National Institute for Health and Care Excellence. Overweight and obesity management (NG246), January 2025.
- National Institute for Health and Care Excellence. Tirzepatide for treating type 2 diabetes (TA924).
- NHS. Who can get free prescriptions.
Monj is an independent price information service operated by Medstack Ltd. It does not sell, prescribe or supply medicines and does not give medical advice. NHS eligibility is decided by NHS clinicians against the criteria current at the time; this page describes those criteria as published. Report suspected side effects through the MHRA Yellow Card scheme.
